Artivion to Release Q1 2026 Financial Results on May 7
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2026
0mins
Source: PRnewswire
- Earnings Release Schedule: Artivion, Inc. will release its Q1 2026 financial results on May 7, 2026, after market close, providing critical financial and statistical information for investor analysis.
- Teleconference Details: The company will hold a teleconference on the release day at 4:30 p.m. ET, hosted by Chairman and CEO Pat Mackin, aimed at discussing financial results in depth and addressing investor questions.
- Replay Access: A replay of the teleconference will be available approximately one hour after the event, accessible by calling 877-660-6853 or 201-612-7415, with the replay conference number being 13759187, ensuring that investors who missed the live session can still obtain relevant information.
- Company Background: Artivion is a medical device company focused on cardiac and vascular surgery, offering products such as aortic stent grafts and surgical sealants, operating in over 100 countries, and dedicated to providing solutions for the challenges faced by surgeons treating aortic diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AORT
Wall Street analysts forecast AORT stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 24.460
Low
40.00
Averages
51.71
High
58.00
Current: 24.460
Low
40.00
Averages
51.71
High
58.00
About AORT
Artivion, Inc. is a medical device company focused on developing solutions that address cardiac and vascular surgeons in treating patients with aortic diseases. The Company operates through two segments, which include Medical Devices and Preservation Services. The Medical Devices segment includes sales of aortic stent grafts, surgical sealants, On-X products, and other products. The Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. It has four product families: aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implantable cardiac and vascular human tissues. Its aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Its surgical sealants include BioGlue Surgical Adhesive products. It is engaged in the endovascular repair of aortic arch disease and the developer of the NEXUS Aortic Arch System.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Artivion Receives FDA Approval for AMDS Hybrid Prosthesis
- FDA Approval: Artivion Inc. has received premarket approval from the U.S. FDA for its AMDS hybrid prosthesis to treat Debakey Type 1 aortic dissections, providing a new option for approximately 6,000 patients annually.
- Clinical Trial Results: The AMDS prosthesis demonstrated a 72% reduction in all-cause mortality and a 54% decrease in major adverse events in the PRESERVE U.S. IDE trial, significantly improving patient survival and treatment outcomes.
- Reduced Surgical Risks: Two-year follow-up data for AMDS treatment showed no re-operations and no occurrences of distal anastomotic new entry (DANE) tears, thereby lowering the risk of future complications for patients.
- Market Impact: The approval allows AMDS to be widely used across U.S. hospitals without requiring further clearance from institutional review boards, which is expected to enhance Artivion's competitiveness in the cardiovascular surgery market, despite its current stock price decline of 3.30%.
See More
Artivion Receives FDA Approval for Innovative Medical Device
- FDA Approval: Artivion, Inc. announced that its AMDS Hybrid Prosthesis has received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA), marking a significant advancement in the medical device sector for treating acute DeBakey Type I aortic dissections.
- Clinical Trial Results: Data from the PERSEVERE U.S. IDE trial demonstrated a 72% reduction in all-cause mortality and a 54% reduction in primary major adverse events, including stroke, renal failure requiring dialysis, and myocardial infarction at 30 days, showcasing the device's superiority over the current standard-of-care hemiarch procedure.
- Market Opportunity: With the PMA approval, Artivion is positioned to fully capitalize on an estimated $150 million annual U.S. market opportunity, further solidifying its leadership in the aortic medical device market.
- Stock Price Reaction: Following the approval, Artivion shares rose more than 2% in pre-market trading, reflecting positive market sentiment towards the company's new product, which closed at $23.61 on the previous trading day.
See More
Artivion Receives FDA Approval for AMDS Hybrid Prosthesis
- FDA Approval: Artivion's AMDS Hybrid Prosthesis has received FDA premarket approval, covering approximately 60% of acute DeBakey Type I aortic dissection cases, marking a significant advancement in the treatment of aortic diseases.
- Administrative Relief: This approval eliminates the need for hospitals to obtain Institutional Review Board (IRB) approval for AMDS implantation, thereby reducing administrative burdens and enabling physicians to treat patients more swiftly.
- Clinical Data Support: Data from the PERSEVERE clinical trial demonstrated a 72% reduction in all-cause mortality and a 54% decrease in major adverse events within 30 days, indicating the device's effectiveness and safety in clinical applications.
- Market Opportunity: The approval of AMDS paves the way for Artivion to tap into an estimated $150 million annual market opportunity in the U.S., expected to accelerate the adoption of this life-saving technology and further solidify the company's leadership in aortic surgical solutions.
See More
Artivion Inc Shares Show Oversold Signal
- Oversold Signal: Artivion Inc (Ticker: AORT) hit an RSI of 29.6 during Thursday's trading, indicating an oversold condition that suggests recent heavy selling may be exhausting, thus providing potential buying opportunities for investors.
- Price Fluctuation: AORT shares reached a low of $20.83, with the current trading price at $21.19, showing a recovery from the 52-week low of $19.16, yet still significantly below the 52-week high of $48.25, indicating volatility and shifts in investor sentiment.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 55.0, AORT's 29.6 RSI indicates relative weakness, potentially attracting investors looking for undervalued stocks, especially in a generally strong market.
- Investor Strategy: Given AORT's RSI nearing oversold territory, investors may consider seeking entry points at this time to capitalize on potential future price rebounds, reflecting market confidence in the stock's recovery prospects.
See More
Artivion to Participate in 2026 MedTech Conference
- Conference Participation: Artivion, Inc. will participate in the Truist Securities MedTech Conference on June 16, 2026, at the Boston Harbor Hotel, showcasing its innovative solutions in cardiac and vascular surgery, which is expected to attract significant attention from industry stakeholders.
- Live Webcast: The company plans to provide a live webcast of the conference on its website, allowing global investors and medical professionals to engage, with a 90-day archived replay available post-event to ensure widespread dissemination of information.
- Product Line Overview: Artivion focuses on developing medical devices for aortic disease, with major products including aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable human tissues, marketed in over 100 countries, demonstrating its strong global market presence.
- Company Background: Headquartered in suburban Atlanta, Georgia, Artivion is dedicated to providing elegant solutions for cardiac and vascular surgeons, addressing significant challenges in treating aortic diseases, thereby reinforcing its leadership position in the medical device industry.
See More
Artivion Completes Acquisition of Endospan to Expand Aortic Product Line
- Acquisition Completed: Artivion has finalized its acquisition of Endospan for $135 million, funded through a previously secured $150 million delayed draw term loan, thereby solidifying its market leadership in aortic disease treatment.
- FDA Approval: The NEXUS branched endovascular stent graft system received FDA premarket approval in April 2026, marking a significant technological advancement for Artivion in treating aortic arch disease, which is expected to drive future sales growth.
- Enhanced Product Portfolio: This acquisition positions Artivion as the only company globally with a complete portfolio of aortic arch solutions, combining the NEXUS system with AMDS and ARCEVO LSA, thereby increasing its competitive edge to meet the growing patient demand.
- Platform Technology Expansion: The NEXUS system represents not just a single product but a platform technology, allowing Artivion to add a robust pipeline of next-generation aortic arch technologies currently in development, which is anticipated to further strengthen its leadership position in the market.
See More
Artivion Receives FDA Approval for AMDS Hybrid Prosthesis
- FDA Approval: Artivion Inc. has received premarket approval from the U.S. FDA for its AMDS hybrid prosthesis to treat Debakey Type 1 aortic dissections, providing a new option for approximately 6,000 patients annually.
- Clinical Trial Results: The AMDS prosthesis demonstrated a 72% reduction in all-cause mortality and a 54% decrease in major adverse events in the PRESERVE U.S. IDE trial, significantly improving patient survival and treatment outcomes.
- Reduced Surgical Risks: Two-year follow-up data for AMDS treatment showed no re-operations and no occurrences of distal anastomotic new entry (DANE) tears, thereby lowering the risk of future complications for patients.
- Market Impact: The approval allows AMDS to be widely used across U.S. hospitals without requiring further clearance from institutional review boards, which is expected to enhance Artivion's competitiveness in the cardiovascular surgery market, despite its current stock price decline of 3.30%.
See More
Artivion Receives FDA Approval for Innovative Medical Device
- FDA Approval: Artivion, Inc. announced that its AMDS Hybrid Prosthesis has received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA), marking a significant advancement in the medical device sector for treating acute DeBakey Type I aortic dissections.
- Clinical Trial Results: Data from the PERSEVERE U.S. IDE trial demonstrated a 72% reduction in all-cause mortality and a 54% reduction in primary major adverse events, including stroke, renal failure requiring dialysis, and myocardial infarction at 30 days, showcasing the device's superiority over the current standard-of-care hemiarch procedure.
- Market Opportunity: With the PMA approval, Artivion is positioned to fully capitalize on an estimated $150 million annual U.S. market opportunity, further solidifying its leadership in the aortic medical device market.
- Stock Price Reaction: Following the approval, Artivion shares rose more than 2% in pre-market trading, reflecting positive market sentiment towards the company's new product, which closed at $23.61 on the previous trading day.
See More
Artivion Receives FDA Approval for AMDS Hybrid Prosthesis
- FDA Approval: Artivion's AMDS Hybrid Prosthesis has received FDA premarket approval, covering approximately 60% of acute DeBakey Type I aortic dissection cases, marking a significant advancement in the treatment of aortic diseases.
- Administrative Relief: This approval eliminates the need for hospitals to obtain Institutional Review Board (IRB) approval for AMDS implantation, thereby reducing administrative burdens and enabling physicians to treat patients more swiftly.
- Clinical Data Support: Data from the PERSEVERE clinical trial demonstrated a 72% reduction in all-cause mortality and a 54% decrease in major adverse events within 30 days, indicating the device's effectiveness and safety in clinical applications.
- Market Opportunity: The approval of AMDS paves the way for Artivion to tap into an estimated $150 million annual market opportunity in the U.S., expected to accelerate the adoption of this life-saving technology and further solidify the company's leadership in aortic surgical solutions.
See More
Artivion Inc Shares Show Oversold Signal
- Oversold Signal: Artivion Inc (Ticker: AORT) hit an RSI of 29.6 during Thursday's trading, indicating an oversold condition that suggests recent heavy selling may be exhausting, thus providing potential buying opportunities for investors.
- Price Fluctuation: AORT shares reached a low of $20.83, with the current trading price at $21.19, showing a recovery from the 52-week low of $19.16, yet still significantly below the 52-week high of $48.25, indicating volatility and shifts in investor sentiment.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 55.0, AORT's 29.6 RSI indicates relative weakness, potentially attracting investors looking for undervalued stocks, especially in a generally strong market.
- Investor Strategy: Given AORT's RSI nearing oversold territory, investors may consider seeking entry points at this time to capitalize on potential future price rebounds, reflecting market confidence in the stock's recovery prospects.
See More
Artivion to Participate in 2026 MedTech Conference
- Conference Participation: Artivion, Inc. will participate in the Truist Securities MedTech Conference on June 16, 2026, at the Boston Harbor Hotel, showcasing its innovative solutions in cardiac and vascular surgery, which is expected to attract significant attention from industry stakeholders.
- Live Webcast: The company plans to provide a live webcast of the conference on its website, allowing global investors and medical professionals to engage, with a 90-day archived replay available post-event to ensure widespread dissemination of information.
- Product Line Overview: Artivion focuses on developing medical devices for aortic disease, with major products including aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable human tissues, marketed in over 100 countries, demonstrating its strong global market presence.
- Company Background: Headquartered in suburban Atlanta, Georgia, Artivion is dedicated to providing elegant solutions for cardiac and vascular surgeons, addressing significant challenges in treating aortic diseases, thereby reinforcing its leadership position in the medical device industry.
See More
Artivion Completes Acquisition of Endospan to Expand Aortic Product Line
- Acquisition Completed: Artivion has finalized its acquisition of Endospan for $135 million, funded through a previously secured $150 million delayed draw term loan, thereby solidifying its market leadership in aortic disease treatment.
- FDA Approval: The NEXUS branched endovascular stent graft system received FDA premarket approval in April 2026, marking a significant technological advancement for Artivion in treating aortic arch disease, which is expected to drive future sales growth.
- Enhanced Product Portfolio: This acquisition positions Artivion as the only company globally with a complete portfolio of aortic arch solutions, combining the NEXUS system with AMDS and ARCEVO LSA, thereby increasing its competitive edge to meet the growing patient demand.
- Platform Technology Expansion: The NEXUS system represents not just a single product but a platform technology, allowing Artivion to add a robust pipeline of next-generation aortic arch technologies currently in development, which is anticipated to further strengthen its leadership position in the market.
See More
